Seminars in Hematology
Volume 45, Supplement 1 , Pages S50-S57, April 2008

Blood-Induced Joint Disease: The Confluence of Dysregulated Oncogenes, Inflammatory Signals, and Angiogenic Cues

The RUSH Hemophilia and Thrombophilia Center, Department of Pediatrics, Rush Children's Hospital and Rush University Medical Center, Chicago, IL.

Hemophilia is a congenital disorder that commonly results in musculoskeletal bleeding and orthopedic complications. After an acute joint hemorrhage, there is pain, swelling, and limited motion due to an increase in intra-articular pressure and inflammation. Increases in intra-articular pressure induce mechanical signals that lead to cartilage cell apoptosis. Repeated bleeding results in development of a target joint, which is characterized by painless swelling and limited motion. Blood in the joint space provokes a proliferative disorder termed hemophilic synovitis (HS), with characteristics resembling those of malignant tumors. It has been suspected that one or more of the many components of blood, particularly iron, may be responsible for initiating and sustaining the inflammatory and synovial/vascular cell proliferation response associated with recurrent joint hemorrhages. In this paper, we review the pathogenesis of HS and present experimental data from mice deficient in factor VIII or IX activity in order to clarify the pathways by which blood in the joint space results in arthropathy. Understanding these pathways and cataloguing their key components may identify new targets for therapy of HS.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 STATEMENT OF CONFLICT OF INTEREST: Leonard Valentino has received grants/research support from Novo Nordisk, Baxter Bioscience, Bayer Healthcare, GlaxoSmithKline, Wyeth, and CSL Behring. He has also served as an advisory board member/consultant for Novo Nordisk, Baxter Bioscience, Wyeth, and CSL Behring, and has served on a speakers' bureau or as a faculty member for Novo Nordisk and Wyeth. Narine Hakobyan has received grant funding from CSL Behring Foundation. Candace Enockson declares no conflict of interest.

PII: S0037-1963(08)00057-7

doi:10.1053/j.seminhematol.2008.03.017

Seminars in Hematology
Volume 45, Supplement 1 , Pages S50-S57, April 2008